Management of hot flashes in breast cancer survivors and men with prostate cancer

Current Oncology Reports

Volumn 6, Issue 4, 2004, Pages 285-290

  Stearns, Vered ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; ANDROGEN; CIMICIFUGA RACEMOSA EXTRACT; CITALOPRAM; CLONIDINE; DIETHYLSTILBESTROL; ESTROGEN; FLUOXETINE; GABAPENTIN; GESTAGEN; GINSENG EXTRACT; MEDROXYPROGESTERONE ACETATE; MEGESTROL ACETATE; MIRTAZAPINE; NORADRENALIN UPTAKE INHIBITOR; PAROXETINE; PHYTOESTROGEN; PLACEBO; PRIMROSE OIL; RED CLOVER EXTRACT; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; SEX HORMONE; SOYBEAN PROTEIN; VENLAFAXINE;

ACUPUNCTURE; BEHAVIOR MODIFICATION; BLEEDING; BODY WEIGHT DISORDER; BREAST CANCER; CANCER SURVIVAL; CHINESE HERB; CLIMACTERIUM; CLINICAL TRIAL; CLOTHING; CONSTIPATION; DIET RESTRICTION; DIZZINESS; DOSE RESPONSE; DRUG WITHDRAWAL; DYSPEPSIA; EXERCISE; FEEDBACK SYSTEM; FEMALE; HEADACHE; HOT FLUSH; HUMAN; HYPOTENSION; LIFESTYLE; MALE; MEDITATION; META ANALYSIS; NAUSEA AND VOMITING; ORCHIECTOMY; ORTHOSTATIC HYPOTENSION; PRESCRIPTION; PROSPECTIVE STUDY; PROSTATE CANCER; RELAXATION TRAINING; REVIEW; SOMNOLENCE; STROKE; SYMPTOM; SYSTEMATIC REVIEW; THROMBOEMBOLISM; TRADITIONAL MEDICINE; TREATMENT FAILURE; TREATMENT OUTCOME; VISUAL DISORDER; WEIGHT GAIN; XEROSTOMIA;

EID: 5444269469     PISSN: 15233790     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11912-004-0037-y     Document Type: Review

References (60)

1. Ganz PA, Rowland JH, Desmond K, et al.: Life after breast cancer: understanding women's health-related quality of life and sexual functioning. J Clin Oncol 1998, 16:501-514.
2. Buchholz NP, Mattarelli G, Buchholz MM: Post-orchiectomy hot flushes. Eur Urol 1994, 26:120-122.
3. Lanfrey P, Mottet N, Dagues F, et al.: Hot flashes and hormonal treatment of prostate cancer. Prog Urol 1996, 6: 7-22.
4. Schow DA, Renfer LG, Rozanski TA, Thompson IM: Prevalence of hot flushes during and after neoadjuvant hormonal therapy for localized prostate cancer. South Med J 1998, 91:855-857.
5. Rossouw JE, Anderson GL, Prentice RL, et al..: Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002, 288:321-333.
6. Beral V: Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003, 362:419-427.
7. Erlik Y, Meldrum DR, Judd HL: Estrogen levels in post-menopausal women with hot flashes. Obstet Gynecol 1982, 59:403-407.
8. Whiteman MK, Staropoli CA, Langenberg PW, et al.: Smoking, body mass, and hot flashes in midlife women. Obstet Gynecol 2003, 101:264-272.
9. Gold EB, Sternfeld B, Kelsey JL, et al..: Relation of demographic and lifestyle factors to symptoms in a multi-racial/ethnic population of women 40-55 years of age. Am J Epidemiol 2000, 152:463-473.
10. Mohyi D, Tabassi K, Simon J: Differential diagnosis of hot flashes. Maturitas 1997, 27:203-214.
11. Kronenberg F: Hot flashes: epidemiology and physiology. Ann N Y Acad Sci 1990, 592:52-86, discussion 123-133.
12. Casper RF, Yen SS: Neuroendocrinology of menopausal flushes: an hypothesis of flush mechanism. Clin Endocrinol (Oxf 1985, 22:293-312.
13. Freedman RR, Krell W: Reduced thermoregulatory null zone in postmenopausal women with hot flashes. Am J Obstet Gynecol 1999, 181:66-70.
14. Freedman RR, Blacker CM: Estrogen raises the sweating threshold in postmenopausal women with hot flashes. Fertil Steril 2002, 77:487-490.
15. Shanafelt TD, Barton DL, Adjei AA, Loprinzi CL: Pathophysiology and treatment of hot flashes. Mayo Clin Proc 2002, 77:1207-1218.
16. Sheard MH, Aghajanian GK: Neural release of brain serotonin and body temperature. Nature 1967, 216:495-496.
17. Salmi P, Ahlenius S: Evidence for functional interactions between 5-HT1A and 5-HT2A receptors in rat thermoregulatory mechanisms. Pharmacol Toxicol 1998, 82:122-127.
18. Berendsen HH: The role of serotonin in hot flushes. Maturitas 2000, 36:155-164.
19. Stearns V, Ullmer L, Lo cent pez JF, et al.: Hot flushes. Lancet 2002, 360:1851-1861.
20. Sloan JA, Loprinzi CL, Novotny PJ, et a.l: Methodologic lessons learned from hot flash studies. J Clin Oncol 2001, 19:4280-4290.
21. Kronenberg F, Fugh-Berman A: Complementary and alternative medicine for menopausal symptoms: a review of randomized, controlled trials. Ann Intern Med 2002, 137:805-813.
22. Tice JA, Ettinger B, Ensrud K, et al.: Phytoestrogen supplements for the treatment of hot flashes: the Isoflavone Clover Extract (ICE) Study: a randomized controlled trial. JAMA 2003, 290:207-214.
23. Jacobson JS, Troxel AB, Evans J, et al.: Randomized trial of black cohosh for the treatment of hot flashes among women with a history of breast cancer. J Clin Oncol 2001, 19:2739-2745.
24. Pockaj B, Loprinzi C, Sloan J, et al.: Pilot evaluation of black cohosh for the treatment of hot flashes in women. Cancer Invest 2004, in press.
25. Messina MJ, Loprinzi CL: Soy for breast cancer survivors: a critical review of the literature. J Nutr 2001, 131: 095S-3108S.
26. Mahady GB: Is black cohosh estrogenic? Nutr Rev 2003, 61:183-186.
27. Barton DL, Loprinzi CL, Quella SK, et al.: Prospective evaluation of vitamin E for hot flashes in breast cancer survivors. J Clin Oncol 1998, 16:495-500.
28. David A, Don R, Tajchner G, Weissglas L: Veralipride: alternative antidopaminergic treatment for menopausal symptoms. Am J Obstet Gynecol 1988, 158:1107-1115.
29. Vercellini P, Vendola N, Colombo A, et al.: Veralipride for hot flushes during gonadotropin-releasing hormone agonist treatment. Gynecol Obstet Invest 1992, 34:102-104.
30. Hammond MG, Hatley L, Talbert LM: A double blind study to evaluate the effect of methyldopa on menopausal vasomotor flushes. J Clin Endocrinol Metab 1984, 58:1158-60.
31. Andersen O, Engebretsen T, Solberg VM, Orbo A: alpha-Methyldopa for climacteric hot flushes: a double-blind, randomized, cross-over study. Acta Obstet Gynecol Scand 1986, 65: 05-409.
32. Nesheim BI, Saetre T: Reduction of menopausal hot flushes by methyldopa: a double blind crossover trial. Eur J Clin Pharmacol 1981, 20:413-416.
33. Goldberg RM, Loprinzi CL, O'Fallon JR, et al.: Transdermal clonidine for ameliorating tamoxifen-induced hot flashes. J Clin Oncol 1994, 12:155-158.
34. Pandya KJ, Raubertas RF, Flynn PJ, et al.: Oral clonidine in postmenopausal patients with breast cancer experiencing tamoxifen-induced hot flashes: a University of Rochester Cancer Center Community Clinical Oncology Program study. Ann Intern Med 2000, 132:788-793.
35. Loprinzi CL, Goldberg RM, O'Fallon JR, et al.: Transdermal clonidine for ameliorating post-orchiectomy hot flashes. J Urol 1994, 151:634-636.
36. Loprinzi CL, Pisansky TM, Fonseca R, et al.: Pilot evaluation of venlafaxine hydrochloride for the therapy of hot flashes in cancer survivors. J Clin Oncol 1998, 16:2377-2381.
37. Stearns V, Isaacs C, Rowland J, et al.: A pilot trial assessing the efficacy of paroxetine hydrochloride (Paxil) in controlling hot flashes in breast cancer survivors. Ann Oncol 2000, 11:17-22.
38. Weitzner MA, Moncello J, Jacobsen PB, Minton S: A pilot trial of paroxetine for the treatment of hot flashes and associated symptoms in women with breast cancer. J Pain Symptom Manage 2002, 23:337-345.
39. Loprinzi CL, Kugler JW, Sloan JA, et al.: Venlafaxine in management of hot flashes in survivors of breast cancer: a randomised controlled trial. Lancet 2000, 356:2059-63.
40. Loprinzi CL, Sloan JA, Perez PA, et al.: Phase III evaluation of fluoxetine for treatment of hot flashes. J Clin Oncol 2002, 20:1578-1583.
41. Stearns V, Beebe KL, Iyengar M, Dube E: Paroxetine controlled release in the treatment of menopausal hot flashes: a randomized controlled trial. JAMA 2003, 289:2827-2834.
42. Stearns V, Isaacs C, Henry-Tillman R, et al.: Paroxetine is an effective therapy for hot flashes: results from a prospective randomized clinical trial [abstract]. Proc ASCO 2003, 22:2940a.
43. Kimmick GG, Lovato J, McQuellon R, et al.: Randomized, placebo-controlled study of sertraline (Zoloft) for the treatment of hot flashes in women with early stage breast cancer taking tamoxifen [abstract]. Proc ASCO 2001, 20:1585a.
44. Barton DL, Loprinzi CL, Novotny P, et al.: Pilot evaluation of citalopram for the relief of hot flashes. J Support Oncol 2003, 1:47-51.
45. Perez D, Loprinzi C, Barton D, et al.: Pilot evaluation of mirtazapine for the treatment of hot flashes. J Support Oncol 2004, 2:1-7.
46. Roth AJ, Scher HI: Sertraline relieves hot flashes secondary to medical castration as treatment of advanced prostate cancer. Psychooncology 1998, 7:129-132.
47. Quella SK, Loprinzi CL, Sloan J, et al.: Pilot evaluation of venlafaxine for the treatment of hot flashes in men under-going androgen ablation therapy for prostate cancer. J Urol 1999, 162:98-102.
48. Loprinzi CL, Barton DL, Carpenter LA, et al.: Pilot evaluation of paroxetine for treating hot flashes in men. Mayo Clin Proc 2004, in press.
49. Stearns V, Johnson MD, Rae JM, et al.: Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J Natl Cancer Inst 2003, 95:1758-1764.
50. Loprinzi CL, Barton DL, Sloan JA, et al.: Pilot evaluation of gabapentin for treating hot flashes. Mayo Clin Proc 2002, 77:1159-1163.
51. Guttuso T Jr, Kurlan R, McDermott MP, Kieburtz K: Gabapentin's effects on hot flashes in postmenopausal women: a randomized controlled trial. Obstet Gynecol 2003, 101:337-345.
52. Thummala AR, Griggs J, Rosenblatt J, et al.: Pilot study using gabapentin on tamoxifen-induced hot flashes in women with breast cancer [abstract]. Proc ASCO 2002, 21:1445a.
53. Chlebowski RT, Hendrix SL, Langer RD, et al.: Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. JAMA 2003, 289:3243-3253.
54. Wassertheil-Smoller S, Hendrix SL, Limacher M, et al.: Effect of estrogen plus progestin on stroke in postmenopausal women: the Women's Health Initiative: a randomized trial. JAMA 2003, 289:2673-2684.
55. Atala A, Amin M, Harty JI: Diethylstilbestrol in treatment of postorchiectomy vasomotor symptoms and its relationship with serum follicle-stimulating hormone, luteinizing hormone, and testosterone. Urology 1992, 39:108-110.
56. Loprinzi CL, Michalak JC, Quella SK, et al.: Megestrol acetate for the prevention of hot flashes. N Engl J Med 1994, 331:347-352.
57. Bullock JL, Massey FM, Gambrell RD Jr: Use of medroxyprogesterone acetate to prevent menopausal symptoms. Obstet Gynecol 1975, 46:165-168.
58. Schiff I, Tulchinsky D, Cramer D, Ryan KJ: Oral medroxyprogesterone in the treatment of postmenopausal symptoms. JAMA 1980, 244:1443-1445.
59. Bertelli G, Venturini M, Del Mastro L, et al.: Intramuscular depot medroxyprogesterone versus oral megestrol for the control of postmenopausal hot flashes in breast cancer patients: a randomized study. Ann Oncol 2002, 13:883-888.
60. Foster GV, Zacur HA, Rock JA: Hot flashes in postmenopausal women ameliorated by danazol. Fertil Steril 1985, 43:401-404.